Project Grant R01AI203565
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Wistar Institute of Anatomy and Biology a Project Grant totaling $887,239 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period May 1, 2026 through April 30, 2031. This award funds research to redirect antibody epitope specificity for HIV-1 vaccine development, addressing a critical barrier in vaccine efficacy: the tendency of soluble envelope...
- Federal Grant Award Summary The Wistar Institute of Anatomy and Biology received a $506,550 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded June 1, 2026, with completion scheduled for May 31, 2028. This cross-sectional research study identifies host plasma biomarkers and SomaLogic disease prognosis scores associated with cell-associated human immunodeficiency virus-1 (HIV-1)...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Wistar Institute of Anatomy and Biology a $162,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 5, 2026, with an ultimate completion date of January 31, 2028. This research initiative, titled "Defining the Single-Cell Epigenetic Landscape of the HIV-1 Reservoir for Effective Latency Reversal," addresses a critical gap in HIV...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded San Diego Biomedical Research Institute a $809,479 Project Grant (CFDA 93.855, Allergy and Infectious Diseases Research) on June 4, 2026, with completion targeted for May 31, 2027. The award funds research to develop engineered HIV-1 envelope glycoprotein (gp120/gp41) trimers designed to induce broadly neutralizing antibodies (BNAbs) protective against HIV infection. Specifically, the research...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Scripps Research Institute a Project Grant totaling $1,285,304 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and evaluate an enhanced HIV vaccine regimen capable of producing durable broadly neutralizing antibody (BNAB) responses. The research, which commenced August 1, 2025, and extends through July 31, 2030, leverages a novel six-shot germline-targeting...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The University of Pennsylvania a Project Grant of $803,591.00 under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective February 3, 2026, with a completion date of January 31, 2031. This research project aims to develop simian-human immunodeficiency virus (SHIV)-infected rhesus macaque models to advance the study of broadly neutralizing antibodies (BNAbs) for HIV-1...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Broad Institute, Inc. a project grant totaling $165,269 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 12, 2026, with a completion date of May 31, 2028. The award funds research directed at evolving human antibody precursors into broadly neutralizing antibodies (BNAbs) against HIV-1, with specific focus on the V2 apex epitope of the HIV-1 envelope...
- Federal Grant Award Summary Award Details: The Scripps Research Institute received a $511,531 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 13, 2026 through January 31, 2031. Products and Services: This project advances HIV vaccine development by incorporating engineered transmembrane envelope (Env) glycoprotein vaccine candidates into stable lipid nanodiscs using...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Scripps Research Institute a Project Grant totaling $931,385 under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of June 10, 2026 and completion date of May 31, 2027. The grant funds research and development of glycoengineered HIV-1 envelope (Env) vaccine immunogens incorporating core α(1,3)-fucose motifs to enhance vaccine efficacy. The...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Pennsylvania a $891,410 Project Grant on August 14, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and test a personalized therapeutic HIV vaccine strategy. The research, scheduled for completion by July 31, 2030, focuses on designing individualized messenger RNA (mRNA)-lipid nanoparticle (LNP) delivered envelope immunogens to boost...
The Wistar Institute of Anatomy and Biology received an $888,042 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 1, 2026 through June 30, 2031. The award supports fundamental biomedical research investigating N332-glycan independent V3-glycan antibodies as novel targets for HIV-1 vaccine design. Specifically, the research develops and evaluates WIN332, an envelope protein-based immunogen lacking the N332-glycan, to elicit broadly neutralizing antibodies (BNAbs) that provide greater neutralization breadth against HIV-1 strains. The study encompasses immunization studies in nonhuman primates to classify and characterize Type-II (N332-glycan independent) V3-glycan antibodies and establish vaccine candidates that streamline BNab development. The deliverables include preclinical research data, immunological characterization of newly identified antibody classes, and scientific publications advancing the understanding of V3-glycan epitope targeting mechanisms. This research contributes to the NIH's broader mission of improving public health by supporting innovative vaccine development strategies aimed at addressing the global HIV/AIDS epidemic. The work is positioned to inform future therapeutic and preventive immunotherapy approaches combining N332-glycan dependent and independent BNabs to impose stronger restrictions on viral escape and suppress viremia for extended periods.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $888.0k | 6/30/26 |